Boothbay Fund Management, LLC Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Boothbay Fund Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$144.95 - $152.29 $1.38 Million - $1.45 Million	9,552 New	9,552 $1.44 Million
Q2 2022 Aug 15, 2022	SELL	$83.14 - $145.99 $611,577 - $1.07 Million	-7,356 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$110.08 - $142.92 $809,748 - $1.05 Million	7,356 New	7,356 $872,000
Q4 2019 Feb 14, 2020	SELL	$40.86 - $57.65 $414,402 - $584,686	-10,142 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$37.38 - $49.47 $344,568 - $456,014	-9,218 Reduced 47.61%	10,142 $423,000
Q2 2019 Aug 14, 2019	BUY	$39.79 - $67.01 $770,334 - $1.3 Million	19,360 New	19,360 $848,000
Q4 2018 Feb 14, 2019	SELL	$29.75 - $42.9 $436,283 - $629,128	-14,665 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$32.79 - $43.0 $480,865 - $630,595	14,665 New	14,665 $551,000
Q2 2018 Aug 14, 2018	SELL	$23.62 - $42.29 $268,275 - $480,329	-11,358 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$22.49 - $34.56 $255,441 - $392,532	11,358 New	11,358 $293,000

792K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $2.8B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.